Material Basis and Mechanism of Erzhi Pill for Preventing Osteoporosis Based on Network Pharmacology
XU Sen-nan1, ZHUANG Li1, ZHAI Yuan-yuan1,2, YAO Wei-feng1,2*, XU Jia1,2, LIU Qi-nan1,2, BAO Bei-hua1,2, CAO Yu-dan1,2, ZHANG Li1,2, DING An-wei1,2
1. Schoolof Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; 2. Jiangsu Key Laboratory for High Technology Research of TCM Formulae and Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China
Abstract��OBJECTIVE To investigate the material basis and action mechanism for preventing osteoporosis of Erzhi Pill through network pharmacology. METHODS Autodock 4.0 was used to establish the interactions of compounds from Erzhi Pill with 36 target proteins related to OP, and the ��ingredient-target-pathway�� network of Erzhi Pill for OP treatment was constructed and analyzed by Cytoscape3.6.0. RESULTS 21 ingredients of Erzhi Pill were found to dock with 35 target proteins(POR,CYP17A1,PTH, et al) and 15 pathways, such as HIF-1 signaling pathway, Rheumatoid arthritis and Thyroid hormone signaling pathway, were affected. CONCLUSION The mechanism of Erzhi Pill for OP treatment may be linked with regulating metabolism pathways, intervening related diseases,adjusting the level of estrogen, and so on, reflecting the action features of multi-ingredients, multi-targets and multi-pathways of traditional Chinese medicine.This study provides new clues for further basic study on the pharmacological mechanism of Erzhi Pill.
��ɭ�, ׯ��, ��, Ҧ����, ���, ������, ������, ���굮, ����, ����ΰ. ��������ҩ��ѧ�о���������ι�������֢�����ʻ��������û���[J]. �й�ҩѧ��־, 2018, 53(22): 1913-1920.
XU Sen-nan, ZHUANG Li, ZHAI Yuan-yuan, YAO Wei-feng, XU Jia, LIU Qi-nan, BAO Bei-hua, CAO Yu-dan, ZHANG Li, DING An-wei. Material Basis and Mechanism of Erzhi Pill for Preventing Osteoporosis Based on Network Pharmacology. Chinese Pharmaceutical Journal, 2018, 53(22): 1913-1920.
BOYANOV M, SHINKOV A, PSACHOULIA E, et al. Baseline characteristics and changes in bone mineral density t-scores of bulgarian women with postmenopausal osteoporosis receiving denosumab in routine clinical practice[J]. Drugs R&D, 2017, 17(1):125-132.
[2]
ZHANG C P, CHEN K, CHEN H P.Research progress of traditional Chinese and western medicine in treating primary osteoporosis[J]. Clin J Tradit Chin Med(��ҽҩ�ٴ���־), 2018, 30(1):171-175.
[3]
CAI X J, HUANG M Y, DING A W, et al. Progress of textual research and pharmacological effects on Erzhi Pills[J]. Chin J Exp Tradit Med Form(�й�ʵ�鷽��ѧ��־), 2011, 17(23):272-275.
[4]
LI S. Network target: a starting point for traditional Chinese medicine network pharmacology[J]. China J Chin Mater Med(�й���ҩ��־), 2011, 36(15):2017-2020.
[5]
ZHU W T, FAN X M, WEI H, et al. Mechanism research of apatinib-treated breast cancer based on network pharmacology[J]. Chin Pharm J(�й�ҩѧ��־), 2014, 49(16):3148-3151.
[6]
ZHANG M M. Life, bones, vitamin D3[J]. Chin J Osteoporos(�й�����������־), 2016, 22(11):1496-1500.
[7]
XU M X, GENG S H, ZHANG Y D, et al. Screening medicinal components of anti-osteoporosis in Epimedii Herba based on FGFR1[J]. Drugs Clin(�ִ�ҩ�����ٴ�), 2017, 32(8):1403-1409.
[8]
LI Y, XIAO Y P, LI J J, et al. Research progress of role of epimedium in promoting osteogenesis of bone marrow mesenchymal stem cells and treating osteogenesis[J]. Chin Pharm J(�й�ҩѧ��־), 2017, 52(24):2137-2140.
[9]
CHO H H, SHIN K K, KIM Y J, et al. NF-��B activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression[J]. J Cell Physiol, 2010, 223(1):168-177.
[10]
YANG X W, HUANG H X, WAN L, et al. Effects of Bcl-2 and BaK gene silencing on cell apoptosis and osteogenesis activity of MG-63 cell lines[J]. J Pract Med(ʵ��ҽѧ��־), 2017, 33(17):2813-2816.
[11]
KANG R R, JIANG D J, YANG S F, et al. Pharmacodynamic study of 3, 5, 4'-trimethoxy-trans-stilbene on osteoarthritis rats after long-term administration[J]. Chin Pharm J(�й�ҩѧ��־), 2014, 49(3):199-203.
[12]
LUO T, LI L F, GUO X Q, et al. Molecular mechanism for inhibitory effect of puerarin on IL6 secretion in human osteoblastlike MG63 cells[J]. Chin Pharmocol Bull(�й�ҩ��ѧͨ��), 2015, 31(11):1524-1529.
[13]
TANG L, CHENG G L, XU Z H. Association between estrogen receptor alphagene(ESR1) PvuII(C/T) and XbaI(A/G) polymorphisms and hip fracture risk:evidence from a Meta-analysis[J]. PLoS One, 2013, 8(12):e82806.
[14]
CHEN J, WU X R, LU L, et al. Effects of estrogen on osteoblast via epithelial sodium channel[J]. Chin Pharm J(�й�ҩѧ��־), 2011, 46(3):180-184.
[15]
MORADI S, MIRZAEI K, ABDURAHMAN A A, et al. Adipokines may mediate the relationship between resting metabolic rates and bone mineral densities in obese women[J]. Osteoporosis Int, 2017, 28(5):1619-1629.
[16]
WANG Y D, TONG J Q, LUO L M, et al. Up-regulation of ER�� in murine osteoblasts with the action of dehydroepiandrosterone[J]. Chin Pharm J(�й�ҩѧ��־), 2006, 41(7):509-512.
[17]
WANG X J, LIN Z J, ZHANG B, et al. Molecular docking analysis of xanthine oxidase inhibition by constituents of cichory[J]. China J Chin Mater Med(�й���ҩ��־), 2015, 40(19):3818-3825.
[18]
YAO C G, XI C L, ZHU X, et al. Expression, purification, evaluation of activity, and analysis of inhibitor docking of enterovirus 71 3C protease[J]. J Pathog Biol(�й���ԭ����ѧ��־), 2017, 12(8):722-726.
[19]
LIU F H, CHEN S J, NI W J. Study on the computer virtual screening of antithrombotic active ingredients in Chuanxiong Rhizoma[J]. J China Pharm(�й�ҩ��), 2017, 28(16):2182-2186.
[20]
HUANG L P, YAN B, HOU M, et al. Study on material basis and mechanism of Erzhi Wan prevent Alzheimer's disease by network pharmacology[J]. China J Chin Mater Med(�й���ҩ��־), 2017, 42(21):4211-4217.
[21]
LI G, ZHANG X A, ZHANG J F, et al. Ethanol extract of Fructus Ligustri Lucidi promotes osteogenesis of mesenchymal stem cells[J]. Phytother Res, 2010, 24(4):571-576.
[22]
KO C H, SIU W S, LAU C P, et al. Osteoprotective effects of Fructus Ligustri Lucidi aqueous extract in aged ovariectomized rats[J]. Chin Med, 2010, 5(1):39.
[23]
HUO Y B, WANG L L, MA R F, et al. Effects of water extract from Ligustri Lucidi Fructus on bone structure and metabolism in ovariectomized rats[J]. Chin Tradit Herb Drugs(�в�ҩ), 2016, 47(7):1155-1162.
[24]
YANG Y, NIAN H L, LIU R H, et al. Effect of Epimedii Folium combined with Ligustri Lucidi Fructus on TGF-��1/Smads pathway in glucocorticoid-induced osteoporosis rats[J]. Chin J Exp Tradit Med Form(�й�ʵ�鷽��ѧ��־), 2017, 23(9):99-104.
[25]
ZHANG Y, LI L, LIN L, et al. Pharmacokinetics, tissue distribution, and excretion of salidroside in rats[J]. Plant Med, 2013, 79(15):1429-1433.
[26]
HUANG R, ZHANG M, RWERE F, et al. Kinetic and structural characterization of the interaction between the FMN binding domain of cytochrome P450 reductase and cytochrome C[J]. J Biol Chem, 2015, 290(8):4843-4855.
[27]
GONG L, ZHANG C M, LV J F, et al. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy[J]. Pharmacogenet Genom, 2017, 27(9):337-346.
[28]
NAPOLI N, RINI G B, SERBER D, et al. The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density[J]. Bone, 2009, 44(3):442-448.
[29]
EDSON K Z, PRASAD B, UNADKAT J D, et al. Cytochrome P450-dependent catabolism of vitamin K: ��-hydroxylation catalyzed by human CYP4F2 and CYP4F11[J]. Biochemistry, 2013, 52(46):8276-8285.
[30]
WANG Q F, LIU Z, LIU J B, et al. Association between CYP11A1 gene polymorphism and osteoporotic fractures in the elderly[J]. Chin J Osteoporos(�й�����������־), 2017, 23(3):303-306, 367.
[31]
SOMNER J, MCLELLAN S, CHEUNG J, et al. Polymorphisms in the P450 c17(7-hydroxylase/17, 0-Lyase) and P450 c19(aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women[J]. J Clin Endocr Metab, 2004, 89(1):344-351.
[32]
HUANG K, HE Q.Relationship between CYP1A1 genetic polymorphism and endometrial cancer: research advances[J]. J Int Pharm Res(����ҩѧ�о���־), 2013, 40(3):277-280.
[33]
XIONG D H, SHEN H, ZHAO L J, et al. Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene-gene interaction[J]. J Bone Miner Res, 2006, 21(11):1678-1695.
[34]
HUANG L T, CHEN Y M, ZHEN X Y.Correlation analysis between parathyroid hormone levels and bone metabolism indexes of chronic kidney disease[J]. J Med Theor Prac(ҽѧ������ʵ��), 2017, 30(7):952-954.
[35]
LI C Y.Effect of parathyroid hormone(1-34) combined with PKP on osteoporotic vertebral compression fracture in the elderly[J]. Chin J Osteoporos(�й�����������־), 2017, 23(4):277-280.
[36]
WEI J, ZHANG Q, SHI L X, et al. Correlation between serum levels of 25(OH)D and PTH and bone mineral density in males in Guiyang city[J]. Chin J Osteoporos(�й�����������־), 2016, 22(5):583-587.
[37]
YAMAMOTO K, OKANO H, MIYAGAWA W, et al. MMP13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1[J]. Matrix Biol, 2016, 56:57-73.
[38]
HUANG T L.The role of CYR61 in DDR2-MMPs signal pathway and the mechanism of induction of RA synovial cell invasion and cartilage erosion by CYR61[D]. Xi'an:The Fourth Military Medical University, 2015.
[39]
CHEN L.Part I: Vertebral fractures in Chinese women aged 50 years and older: prevalence and potential risk factors.Part ��: A novel homozygous mutation in the HPGD gene causes primary hypertrophic osteoarthropathy [D]. Beijing:Peking Union Medical College, 2012.
[40]
WANG B Y, PAN J.Tanshinol attenuates oxidative stress-induced osteoporosis and reduces apoptosis of osteoblasts via PI3/Akt signal pathway[J]. Chin J Osteoporos(�й�����������־), 2017, 23(1):1-11.
[41]
XUE S T, GUO H F, LIU M J, et al. Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2-up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats[J]. Eur J Med Chem, 2015, 96: 151-161.
[42]
CHEN X X, DENG W M, WEI Q S, et al. Investigation of the pathogenesis of senile osteoporosis from GH/IGF-1 axis and PI3K/Akt pathway[J]. Chin J Osteoporos(�й�����������־), 2015, 21(11):1412-1415.
[43]
KAWASUMI H, GONO T, TANAKA E, et al. Clinical characteristics and cytokine profiles of organizing pneumonia in patients with rheumatoid arthritis treated with or without biologics[J]. J Rheumatol, 2016, 43(4):738-744.
[44]
LIN H X, WANG D Y.Relationship between changes of serum IL-34, RF and RANKL levels in patients with rheumatoid arthritis and osteoporosis[J]. Int J Lab Med(���ʼ���ҽѧ��־), 2017, 38(18):2540-2542.
[45]
ZHONG H, CAO C, YANG J, et al. Research on relationship of HIF-1 signaling pathway and postmenstrual osteoporosis[J]. J Sichuan Univ(Med Sci Ed)(�Ĵ���ѧѧ��:ҽѧ��), 2017, 48(6):862-868.
[46]
ISOMOTO S, HATTORI K, OHGUSHI H, et al. Rapamycin as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells[J]. J Orthop Sci, 2007, 12(1):83-88.
[47]
XU S.mTORC1 regulates ��-catenin RANKL/OPG and osteoclastogenesis through beta-cateninsignaling pathway[D]. Guangzhou:Southern Medical University, 2013.
[48]
YIN W L, YOU X Y.Vitamin D receptor gene polymorphism in hyperthyroidism patients with osteoporosis[J]. Chin J Exp Surg(�л�ʵ�������־), 2017, 34(8):1414-1415.
[49]
LIU S T.Research of serum interleukin-6, souble IL-6 receptor and bone metabolism in patients with Grave's disease [D]. Soochow:Soochow University, 2001.
[50]
LIANG L.The associations of serum levels of irisin and FGF21 with body composition and bone mineral density in postmenopausal women with type 2 diabetes mellitus[D]. Jinan: Shangdong University, 2017.
[51]
ZHANG J. The Impact of vitamin D status on insulin resistance and bone metabolis minpatients with Type 2 diabetes and it's potential mechanisms[D]. Guangzhou: Southern Medical University, 2017.
[52]
ZHENG H X, ZHAO Y, XU Y, et al. Estrogenic effect of Erzhiwan on immature mice[J]. Chin J Exp Tradit Med Form(�й�ʵ�鷽��ѧ��־), 2018, 24(4):103-107.
[53]
CHEN Y Q, OU Q Z, CHEN Q, et al. The rapeutic effect of ovary tissue allotransplantation on the osteoporosis of ovariectomized rat model[J]. Acta Laser Biol Sin(��������ѧ��), 2017, 26(6):544-556.
[54]
CHEN T G, GOU Y, TIAN F M, et al. Research progresses on the effects of estrogen and selective estrogen receptor modulators on osteoarthritis[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2018, 34(1):73-76.
[55]
WANG L, LI D J, WANG W J, et al. Modulation of dehydroepiandrosterone on mRNA transcription of estrogen receptor isoforms and aromatase in murine osteoblasts[J]. Chin Pharm J(�й�ҩѧ��־), 2006, 41(6):427-430.
[56]
NELEON E R, WARDELL S E, MCDONNELL D P. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis[J]. Bone, 2013, 53(1):42-50.
[57]
JOAQUIN C A, PLUVIO C M.Third generation selective estrogen receptor modulators: benefits beyond bone[J]. Med Clin(Barc), 2013, 140(6):266-271.
2018, Vol. 53 
